Actively Recruiting
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-03-17
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how droplet digital PCR (ddPCR) can help identify harmful bacteria early in patients admitted to the intensive care unit (ICU) with sepsis. This observational study aims to track the presence and amount of bacteria in the blood over time and understand how these bacteria relate to patients' clinical conditions and outcomes. The study is conducted at a single center and focuses on critically ill ICU patients with their first sepsis diagnosis. Patients in this study will have their blood tested at various points from admission up to 28 to 30 days or until they leave the ICU. The ddPCR method will be used to monitor the amount of bacterial genetic material in their blood dynamically. This ongoing monitoring helps researchers observe changes in bacterial presence during the critical period of sepsis treatment. Participants will undergo repeated blood sampling at specified intervals: days 0, 2-3, 4-5, 6-7, 8-9, 10-12, 13-15, 20-22, and 28-30 after ICU admission. Researchers will measure bacterial nucleic acid loads at these times and track survival status at 28 days after the initial sepsis diagnosis. This monitoring helps assess the relationship between bacterial levels and patient outcomes throughout the observation period.
CONDITIONS
Brief Title
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with first diagnosis of sepsis after ICU admission
You will not qualify if you...
- Age under 18 years
- Do not meet Sepsis 3.0 diagnostic criteria
- Refusal to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 to 30 days or until ICU discharge
Participants are dynamically monitored for nucleic acid loads of pathogenic bacteria in the blood at different time points until day 28-30 or discharge from the ICU.
Multiple blood sample collections at scheduled intervals during ICU stay
Trial Site Locations
Total: 1 location
1
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Actively Recruiting
Research Team
Y
You Shang, prof.
X
Xiaobo Yang, prof.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here